129 related articles for article (PubMed ID: 3859676)
21. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
22. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
23. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
24. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report.
Faggiano P; D'Aloia A; Bignotti T; Dei Cas L
Ital Heart J; 2003 Jul; 4(7):497-9. PubMed ID: 14558304
[TBL] [Abstract][Full Text] [Related]
25. [Incidence of CA 125 antigen in the blood of women with ovarian carcinoma].
Tosner J; Lacinová V; Louda B; Vanásek J
Cesk Gynekol; 1987 Nov; 52(9):681-4. PubMed ID: 3482173
[No Abstract] [Full Text] [Related]
26. [CA 125 in diagnosis and prognosis of epithelial ovarian cancer].
Cohen AD; Piura B; Cohen Y; Shoenfeld Y
Harefuah; 1994 Mar; 126(5):283-5, 303. PubMed ID: 8188111
[TBL] [Abstract][Full Text] [Related]
27. [CA-125: a serum tumor marker in ovarian cancer].
Cohen AD; Piura B; Cohen Y
Harefuah; 1994 Feb; 126(3):154-9. PubMed ID: 8168751
[No Abstract] [Full Text] [Related]
28. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
29. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
30. Clinical correlations of ovarian cancer antigen NB/70K: a preliminary report.
Dembo AJ; Chang PL; Urbach GI
Obstet Gynecol; 1985 May; 65(5):710-4. PubMed ID: 3856794
[TBL] [Abstract][Full Text] [Related]
31. [CA 125--a new characteristic in the diagnosis of ovarian carcinoma].
Tosner J
Cesk Gynekol; 1987 Jun; 52(5):381-5. PubMed ID: 3477330
[No Abstract] [Full Text] [Related]
32. CA-125 ovarian cancer associated antigen in cancer and pregnancy: interpretation of enzyme immunoassay and immunoradiometric assay.
Touitou Y; Bogdan A; Darbois Y
Anticancer Res; 1989; 9(6):1805-7. PubMed ID: 2697189
[TBL] [Abstract][Full Text] [Related]
33. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
35. [Comments on the paper by Schröck et al., The simultaneous determination of Ca 125 and D-dimer in plasma and ascitic fluid in ovarian cancer].
Mezger J
Onkologie; 1986 Feb; 9(1):10. PubMed ID: 3523340
[No Abstract] [Full Text] [Related]
36. [CA 125 in benign and malignant pathology of the female genital tract and neoplasms of the gastrointestinal tract].
Debiasi D; Gramellini D; Montagna S; Calbiani B; Franchini D; Capocasale E; Capelli P; Casoni P
Minerva Ginecol; 1988 Mar; 40(3):153-7. PubMed ID: 3173763
[No Abstract] [Full Text] [Related]
37. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of the CA-125 assay for the management of patients with ovarian carcinoma.
Raju RN; Dalbow MH; Pugh RP; Concannon JP; Zidar BL; Zamerilla CF; Schenken LL
Prog Clin Biol Res; 1987; 248():289-97. PubMed ID: 3478733
[No Abstract] [Full Text] [Related]
39. CA-125 serum concentrations during the menstrual cycle.
Jäger W; Meier C; Wildt L; Sauerbrei W; Lang N
Fertil Steril; 1988 Aug; 50(2):223-7. PubMed ID: 3165071
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
